This activity is designed to help urology advanced practice providers and nurses understand best practice approaches for identifying metastatic hormone-sensitive prostate cancer to ensure optimal patient outcomes.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 3/5/25.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):

Planning Committee Disclosures:
Diane Newman, DNP, CRNP, FAAN, BCB-PMD - Advisory Board for EBT Medical, Coloplast, and ConvaTec; conducts research for Hollister; editor for Digital Science Press

There are no other Planning Committee disclosures to declare.

Speaker Disclosures:
Leanne Schimke, MSN, CRNP, CUNP, FNP-C - Speaker for Bayer & Pfizer

Commercial Support:
Sponsored by an unrestricted grant from Bayer HealthCare Pharmaceuticals Inc.

No other commercial support declared.

Accreditation Statement:
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this learning activity, the participant will be able to recognize individual patient disease/treatment characteristics to facilitate appropriate treatment strategies to optimize care for patients with metastatic hormone-sensitive prostate cancer.